Present Research:

  1. Triple-Negative Breast Cancer (TNBC) is the most aggressive, invasive, and metastatic among breast cancer subtypes. There are limited therapeutic options for TNBC to date. As TNBCs don’t express any hormone receptors, therapeutic strategies targetting hormone receptors for other subtypes of BC don’t work for TNBC. Epidermal Growth Factor Receptor (EGFR or HER1) is expressed by TNBCs. Our present goal is to develop a small peptide-based delivery system targetting EGFR to deliver anticancer agents into TNBC cells without affecting non-cancer cells.
  2. Heat shock protein 90 (Hsp90) is a chaperone protein, expressed in many cancers including breast cancer. Hsp90 has been studied extensively but there is no evidence showing any connections between microRNAs and Hsp90 in breast cancers. Our goal is to find out the microRNAs which are correlated with Hsp90 in the development and progression of breast cancer and to study the mechanistic roles of the microRNAs in vitro and in vivo.
  1. Ramalingaswami Fellow, Department of Biotechnology, Govt. of India, July 2019-June 2024
  2. Post-Doctoral Research Associate, Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, USA, February 2015- June 2019
  3. Post-Doctoral Research Associate, Department of Urology, University of Pittsburgh, Pittsburgh, USA, Feb 2014- Jan 2015
  4. Ph.D., CSIR-Indian Institute of Chemical Technology, Hyderabad, India, Aug 2007- Jan 2014
  5. Master of Science, Indian Institute of Technology, Kharagpur (IIT-Kgp), 2005-2007
  6. Bachelor of Science, University of Calcutta, Kolkata, 2002-2005
  1. Subrata K Pore, Hahm ER, Kim S, Singh KB, Nyiranshuti L, Latoche JD, Anderson CJ, Adamik J, Galson DL, Weiss KR, Watters RJ, Lee B, Kumta PN, and Singh SV. A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer-Induced Osteolytic Bone Resorption. Molecular Cancer Therapeutics 2019 (Impact factor: 4.9)
  1. Subrata K Pore*, Ganguly A, Sau S, Godeshala S, Kanugula AK, Ummanni R, Kotamraju S, and Banerjee R*. N-end rule pathway inhibitor sensitizes cancer cells to antineoplastic agents by regulating XIAP and RAD21 protein expression. J Cell. Biochem. 2020, 121(1), 804-815 *corresponding author (Impact factor: 3.5)
  2. Subrata K Pore, Hahm ER, Latoche JD, Anderson CJ, Shuai Y, and Singh SV. Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanate. Carcinogenesis 2018, 39(2):134-145 (Impact Factor: 5.1)
  1. Subrata K Pore, Choudhary A, Rathore B, Ganguly A, Sujitha P, Kumar CG, Agawane SB, Kumar JM, Scaria V, Pillai B and Banerjee R. Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect. Biomaterials 2013, 34(28):6804-6817 (Impact Factor: 10.3)
  1. Jiang Y#, Subrata K Pore#, Lee JH, Sriram S, Mai BK, Han DH, Zakrzewska A, Kim Y, Banerjee R, Lee S and Lee MJ. Characterization of mammalian N-degrons and development of heterovalent inhibitors of the N-end rule pathway. Chemical Science 2013, 4:3339-3346. (#Equal contribution) (Impact Factor: 8.7)
  1. Subrata K Pore, Bose D, Maiti S and Banerjee R. Streptomycin, inhibition of miR-21, reduces invasion and suppresses tumor growth. Indian Journal of Biochemistry & Biophysics, 2015, 52:227-231 (Impact Factor: 0.958)
  1. Kashyap M#, Subrata K Pore#, Chancellor M, Yoshimura N, Tyagi P. Bladder overactivity involves overexpression of MicroRNA 132 and nerve growth factor. Life Sci. 2016, 167:98-104 (#Equal contribution) (Impact Factor: 2.7)
  1. Subrata K Pore, Banerjee R. The N-end rule pathway: Its physiological importance and role in disease pathology. International Journal of Pharmaceutical Sciences Review and Research 2013, 23(1), 266-274 (Impact Factor: 2.2)
  1. Kashyap M, Subrata K Pore, de Groat WC, Chermansky C, Yoshimura N, Tyagi P. BDNF overexpression in bladder induces neuronal changes to mediate bladder overactivity. Am J Physiol Renal Physiol. 2017, 315 (1): F45-F56 (Impact Factor: 3.6)
  2. Kashyap M, Subrata K Pore, Yoshimura N, Tyagi P. Constitutive expression of NGF and P75NTR affected by bladder distension and NGF antisense treatment. Life Sci. 2016, 148:93-98 (Impact Factor: 2.7)
  1. Kashyap M, Subrata K Pore, Wang Z, Gingrich J, Yoshimura N, and Tyagi P. Inflammasomes are important mediators of prostatic inflammation associated with BPH. Journal of Inflammation 2015, 12: 37 (Impact Factor: 2.22)
  2. Pal K, Subrata K Pore, Sinha S, Janardhanan R, Mukhopadhyay D, and Banerjee R. Structure-activity study to develop cationic lipid-conjugated haloperidol derivatives as a new class of anticancer therapeutics. Med. Chem. 2011, 54:2378-2390 (Impact Factor: 6.26)
  3. Sehrawat A, Roy R, Subrata K Pore, Hahm ER, Samanta SK, Singh KB, Kim SH, Singh K, Singh SV. Mitochondrial dysfunction in cancer chemoprevention by phytochemicals from dietary and medicinal plants. Semin Cancer Biol. 2016, 47:147-153 (Impact Factor: 9.96)
  4. Singh KB, Hahm ER, Subrata K Pore, and Singh SV. Leelamine is a Novel Lipogenesis Inhibitor in Prostate Cancer Cells In Vitro and In Vivo. Mol Cancer Ther. 2019 doi: 10.1158/1535-7163.MCT-19-0046. (Impact Factor: 4.86)
  1. Singh KB, Kim SH, Hahm ER, Subrata K Pore, Jacobs BL, Singh SV. Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism. Carcinogenesis. 2018, 39:826-837 (Impact factor: 4.0)
  1. Bose D, Jayaraj G, Suryawanshi H, Agarwala P, Subrata K Pore, Banerjee R, and Maiti S. The tuberculosis drug streptomycin as potential cancer therapeutic: Inhibition of miR-21 function by directly targeting its precursor. Chem. Int. Ed. 2012, 51:1019-1023 (Impact Factor: 11.99)
  2. Samanta SK, Sehrawat A, Kim SH, Hahm ER, Shuai Y, Roy R, Subrata K Pore, Singh KB, Christner SM, Beumer JH, Davidson NE, Singh SV. Disease subtype-independent biomarkers of breast cancer chemoprevention by the ayurvedic medicine phytochemical Withaferin A. J Natl Cancer Inst. 2017, 109(6) doi: 10.1093/jnci/djw293 (Impact Factor: 11.4)
  1. Yadav V, Kumar A, Mann A, Aggarwal S, Kumar M, Subrata K Pore, Banerjee R, Kumar MJ, Thakur R and Chowdhury S. Engineered reversal of drug resistance in cancer cells – metastases suppressor factors as change agents. Nucleic Acid Research 2014, 42(2):764-773 (Impact Factor: 10.1)
  1. Smith PP, Tyagi P, Kuchel GA, Subrata K Pore, Chermansky C, Chancellor M, Yoshimura N and Levanovich P. Advanced therapeutic directions to treat the underactive bladder. International Urology and Nephrology, 2014, 46(1):35-44 (Impact Factor: 1.29)
  1. Tyagi P, Motley SS, Kashyap M, Subrata K Pore, Gingrich J, Wang Z, Yoshimura N, and Fowke HJ. Urine chemokines indicate pathogenic association of obesity with BPH/LUTS. International Urology and Nephrology 2015, 47(7):1051-1058 (Impact Factor: 1.29)
  1. Tyagi P, Kadekawa K, Kashyap M, Subrata K Pore, Yoshimura N. Spontaneous recovery of reflex voiding following spinal cord injury mediated by anti-inflammatory and neuroprotective factors. Urology 2016, 88:57-65 (Impact Factor: 2.4)

Ongoing Project: Development of Hsp90-regulating microRNA-based therapeutics for breast cancer. DBT, Govt. of India